Advertisement

Search Results

Advertisement



Your search for all items matches 269 pages

Showing 1 - 50


hematologic malignancies

Case 3: Managing Myelofibrosis Beyond the First-Line Setting

This is Part 3 of Expert Perspectives on the Treatment of High-Risk Myelofibrosis, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable.    In this video, Drs. Abdulraheem Yacoub, Gabriela Hobbs, and Douglas Tremblay discuss the treatment of a 70-year-old ...

hematologic malignancies

Case 1: Initial Management of a Patient With High-Risk Myelofibrosis

This is Part 1 of Expert Perspectives on the Treatment of High-Risk Myelofibrosis, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable.    In this video, Drs. Abdulraheem Yacoub, Gabriela Hobbs, and Douglas Tremblay discuss the treatment of a 67-year-old ...

hematologic malignancies

Andrew Kuykendall, MD, on Hepcidin Mimetic for Polycythemia Vera

Andrew Kuykendall, MD, of Moffitt Cancer Center, discusses findings from the phase III VERIFY trial, which compared the efficacy of rusfertide vs placebo in patients with polycythemia vera who continue their current standard of care therapy (Abstract LBA3). 

hematologic malignancies
supportive care

Masumi Ueda Oshima, MD, on, a Posttransplant GVHD Prophylaxis Strategy

Masumi Ueda Oshima, MD, of Fred Hutchinson Cancer Center, discusses findings from a phase II trial exploring the use of cyclosporine and sirolimus combined with mycophenolate mofetil or posttransplant cyclophosphamide as graft-vs-host disease (GVHD) prophylaxis.

hematologic malignancies
supportive care

John Magenau, MD, on Alpha-1-Antitrypsin for High-Risk Acute GVHD

John Magenau, MD, of the University of Michigan, presents results from the phase III BMT CTN 1705 trial, which explored the efficacy of alpha-1-antitrypsin (AAT) plus corticosteroids vs corticosteroids alone for the treatment of high-risk acute graft-vs-host disease (GVHD) following allogeneic...

hematologic malignancies
supportive care

Kristina Maas-Bauer, MD, on ROCK1/2 Inhibition and GVHD

Kristina Maas-Bauer, MD, of the University of Freiburg, discusses preclinical research on the role of ROCK1/2 in graft-vs-host disease (GVHD), which found an effect on myeloid cells, both in phenotype profile and migration capabilities. Additionally, she discusses the potential of combining ROCK1/2 ...

hematologic malignancies
supportive care

Betty Hamilton, MD: Research Highlights in GVHD

Betty Hamilton, MD, of Cleveland Clinic, outlines key data from a clinical session she co-chaired on graft-vs-host disease (GVHD), including the role of JAK inhibitors in the prevention of the condition and novel therapies for the management of acute GVHD.

hematologic malignancies

Case 3: Steroid-Refractory Chronic GVHD With Sclerosis

This is Part 3 of Treatment Sequencing Considerations for Chronic Graft-vs-Host Disease, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable.   In this video, Drs. Corey Cutler, Betty K. Hamilton, and Hannah K. Choe discuss the management of...

hematologic malignancies

Case 2: Moderate Chronic GVHD

This is Part 2 of Treatment Sequencing Considerations for Chronic Graft-vs-Host Disease, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable.   In this video, Drs. Corey Cutler, Betty K. Hamilton, and Hannah K. Choe discuss the management of moderate...

hematologic malignancies

Case 1: Acute GVHD in a Patient With Lymphoma

This is Part 1 of Treatment Sequencing Considerations for Chronic Graft-vs-Host Disease, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable.   In this video, Drs. Corey Cutler, Betty K. Hamilton, and Hannah K. Choe discuss the first-line treatment of...

hematologic malignancies

Patient With Transfusion-Dependent Myelofibrosis and Severe Thrombocytopenia

This is Part 3 of Personalizing Therapy for Myelofibrosis, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable.   In this video, Drs. Andrew Kuykendall, Anthony Hunter, and Stephen Oh discuss the management of a transfusion-dependent patient with...

hematologic malignancies

Patient With Ruxolitinib-Treated Myelofibrosis Who Develops Anemia

This is Part 2 of Personalizing Therapy for Myelofibrosis, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable.   In this video, Drs. Andrew Kuykendall, Anthony Hunter, and Stephen Oh discuss the management of a patient with myelofibrosis who develops...

hematologic malignancies

Patient With Newly Diagnosed Myelofibrosis and Moderate Anemia

This is Part 1 of Personalizing Therapy for Myelofibrosis, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable.   In this video, Drs. Andrew Kuykendall, Anthony Hunter, and Stephen Oh discuss the first-line treatment of a newly diagnosed patient with...

solid tumors
hematologic malignancies

Justin Arnall, PharmD, BCOP, FCCP, on Complicating “Factors”: When Malignancy and Non-Malignant Hematology Collide

Justin Arnall, PharmD, BCOP, FCCP, of Atrium Health Specialty Pharmacy Service in Charlotte, North Carolina, discusses his JADPRO Live presentation on critical considerations when planning for cancer-related procedures in patients with hereditary/congenital as well as acquired bleeding disorders.

hematologic malignancies

Erik Thiele Orberg, MD, PhD, on Recovery of the Intestinal Microbiome in Patients at Day +100 after Allogeneic Stem Cell Transplantation Is Defined by Microbial Metabolite Profiles and Linked to Long-Term Outcomes

Erik Thiele Orberg, MD, PhD, of University Hospital Regensburg, shares findings of a longitudinal, prospective study investigating microbial and metabolite recovery in the post-transplant period. He discusses how these findings could have significant implications for future microbiome-modulating...

hematologic malignancies

Hannah Choe, MD, on Dynamics of Overall and Organ-Specific Responses to Axatilimab in Chronic Graft-Versus-Host Disease: Analysis from the AGAVE-201 Study

Hannah Choe, MD, of The Ohio State University Comprehensive Cancer Center – James Cancer Hospital, reviews results from a secondary analysis of the phase 2 AGAVE-201 study, which assessed axatilimab, an anti-colony stimulating factor 1 receptor monoclonal antibody, in the setting of chronic...

hematologic malignancies

Jenny Paredes, PhD, on How Increased Fiber Intake Results in Better Overall Survival and Lower GI-aGVHD in Allo-HCT Recipients and Pre-Clinical GVHD Models

Jenny Paredes, PhD, of City of Hope National Medical Center, discusses a study investigating the effects of dietary fiber on acute graft-versus-host disease (aGVHD) after allogeneic hematopoietic cell transplantation (allo-HCT). The researchers evaluated a preclinical mouse model of GVHD with...

hematologic malignancies

John O. Mascarenhas, MD, on Myelofibrosis: Novel Combination of Imetelstat Plus Ruxolitinib

John O. Mascarenhas, MD, of Icahn School of Medicine at Mount Sinai, discusses early results from the ongoing phase I/IB IMproveMF trial, which is evaluating the safety and activity of the novel combination of imetelstat and ruxolitinib in patients with intermediate- or high-risk myelofibrosis...

hematologic malignancies

John O. Mascarenhas, MD, on Relapsed/Refractory Myelofibrosis: Navtemadlin vs Best Available Therapy After JAK Inhibitor Treatment

John O. Mascarenhas, MD, of Icahn School of Medicine at Mount Sinai, discusses the results of the phase III BOREAS study evaluating the efficacy and safety of single-agent navtemadlin vs best available therapy in patients with relapsed/refractory myelofibrosis who had previously received JAK...

hematologic malignancies
supportive care

Nikolaos Katsivelos, MD, and John Levine, MD, MS, on How Serial Clinical and Biomarker Monitoring During Treatment Can Stratify Patients With Low-Risk GVHD

Nikolaos Katsivelos, MD, and John Levine, MD, MS, of Icahn School of Medicine at Mount Sinai report on an investigation into the potential for serial monitoring of graft-versus-host disease (GVHD) symptom severity and MAGIC algorithm probabilities in patients with clinical and biomarker-defined...

solid tumors
hematologic malignancies

Wendy Vogel, MSN, FNP, AOCNP, FAPO, on the Evolving Role of Advanced Practice Providers in Oncology Care

Wendy Vogel, MSN, FNP, AOCNP, FAPO, of the Advanced Practitioner Society for Hematology and Oncology, summarizes a panel discussion in which she took part, on forming interprofessional oncology care teams that include advanced practitioners. Such collaboration may improve patient outcomes and help...

hematologic malignancies

Managing Treatment-Emergent Anemia in a Patient With Myelofibrosis

This is Part 1 of Addressing Unmet Needs in Myelofibrosis, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable.   In this video, Drs. John Mascarenhas, Gabriela Hobbs, and Abdulraheem Yacoub discuss the management of treatment-emergent anemia in a...

hematologic malignancies

Andrew Srisuwananukorn, MD, on Myelofibrosis vs Essential Thrombocythemia: A Potential New Clinical Decision Tool

Andrew Srisuwananukorn, MD, of The Ohio State University Comprehensive Cancer Center, discusses a novel artificial intelligence model that can distinguish between prefibrotic primary myelofibrosis and essential thrombocythemia. This proposed model may assist clinicians in identifying patients who...

hematologic malignancies
issues in oncology

Sara Khan, DO, on the Gender Gap in Receiving NIH Grants for Hematology Research

Sara Khan, DO, of the University of South Florida Morsani College of Medicine and HCA Healthcare, discusses her findings showing that women received only 33% of grants from the National Institutes of Health from 2012 to 2022 in nonmalignant hematologic research. Although some agencies have made...

hematologic malignancies
genomics/genetics

Potential Clinical Uses of Identifying New Hematologic Malignancy Predisposition Gene

Hamish S. Scott, PhD, and Chris Hahn, PhD, both of Australia’s SA Pathology and Centre for Cancer, discuss ERG, a new predisposition gene for bone marrow failure and hematologic malignancy. Identifying causal germline ERG variants has direct clinical implications for diagnosis, counseling,...

hematologic malignancies
leukemia
lymphoma
myelodysplastic syndromes

Mikkael A. Sekeres, MD, on Therapies for Hematologic Cancers: Is More or Less Better?

Mikkael A. Sekeres, MD, of the Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine, reviews key abstracts from ASH 2023 on treatment of myelofibrosis, chronic lymphocytic leukemia, large B-cell lymphoma, and acute myeloid leukemia (Abstracts 620, 631, 781,...

hematologic malignancies
leukemia

Nicholas J. Short, MD, on Acute Lymphoblastic Leukemia: New Analysis of Ponatinib and Blinatumomab

Nicholas J. Short, MD, of The University of Texas MD Anderson Cancer Center, discusses findings from a phase II study subgroup analysis that explored the question of whether ponatinib and blinatumomab, both active in Philadelphia chromosome–positive acute lymphoblastic leukemia, could offer an...

hematologic malignancies

Rami S. Komrokji, MD, on Myelodysplastic Neoplasms: Classifying Risks Among Subsets of Disease

Rami S. Komrokji, MD, of Moffitt Cancer Center, discusses an assessment of new classifications for myeloid neoplasms and the ongoing efforts to harmonize these classifications, so researchers can better understand risk, outcomes, and survival among patients with genetically distinct types of the...

hematologic malignancies
leukemia

Nigel Russell, MD, on Acute Myeloid Leukemia: New Findings on FLAG-Ida and Gemtuzumab Ozogamicin

Nigel Russell, MD, of Guy’s and St. Thomas’ NHS Foundation Trust, discusses the latest results from the AML19 trial, which showed the chemotherapy regimen FLAG-Ida (fludarabine, high-dose cytarabine, idarubicin, and granulocyte-colony stimulating factor), when combined with gemtuzumab ozogamicin,...

lymphoma
hematologic malignancies
immunotherapy

Matthew J. Frank, MD, PhD, on Large B-Cell Lymphoma: New Data on CD22 CAR T-Cell Therapy

Matthew J. Frank, MD, PhD, of Stanford University School of Medicine, discusses new findings showing that CD22 chimeric antigen receptor (CAR) T-cell therapy is an effective and safe salvage therapy for patients with CAR19-refractory large B-cell lymphoma. A multicenter phase II clinical trial is...

leukemia
hematologic malignancies

Jennifer R. Brown, MD, PhD, on CLL: Resistance to Pirtobrutinib in Pretreated Disease

Jennifer R. Brown, MD, PhD, of Dana-Farber Cancer Institute, discusses phase I/II findings from the Bruin study of resistance to pirtobrutinib in patients with covalent BTK inhibitor–pretreated chronic lymphocytic leukemia (CLL). The aim of the study was to explore the genomic evolution of...

hematologic malignancies

Goals of Care in Primary Myelofibrosis

This is Part 3 of Updates in Myeloproliferative Neoplasms, a three-part video roundtable series.   In this video, Dr. Naveen Pemmaraju and Dr. Gabriela Hobbs discuss goals of care in primary myelofibrosis.   The patient is a 27-year-old woman who presents to the clinic after 6 months of...

hematologic malignancies
leukemia

Deborah M. Stephens, DO, on CLL/SLL: NCCN Clinical Practice Guidelines in Oncology® Update

Deborah M. Stephens, DO, of the Huntsman Cancer Institute at the University of Utah, discusses NCCN’s updates to treatment recommendations for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma. Dr. Stephens details the key factors in selecting front-line and subsequent...

hematologic malignancies

Early Detection of Chronic Graft-vs-Host Disease

This is Part 1 of Clinical Considerations in Chronic Graft-vs-Host Disease, a two-part video roundtable series.   In this video, Dr. Yi-Bin Chen and Dr. Mitchell E. Horwitz discuss the case of a 55-year-old man with FLT3-ITD–mutated acute myeloid leukemia in first complete remission who received a...

hematologic malignancies

Myelofibrosis-Related Anemia

This is Part 2 of Updates in Myeloproliferative Neoplasms, a three-part video roundtable series.   In this video, Dr. Srden Verstovsek and Dr. Abdulraheem Yacoub discuss the management of patients with anemia as a presenting symptom of myelofibrosis.   The patient is a 68-year-old woman who...

hematologic malignancies
genomics/genetics

Smita Bhatia, MD, MPH: Some Clonal Mutations May Predict Therapy-Related Myeloid Neoplasms

Smita Bhatia, MD, MPH, of the Institute for Cancer Outcomes and Survivorship, University of Alabama at Birmingham, discusses study findings that showed key somatic mutations in the peripheral blood stem cell product increases the risk of developing therapy-related myeloid neoplasms (Abstract 119).

hematologic malignancies
immunotherapy

Joseph Schroers-Martin, MD, on Posttransplant Lymphoproliferative Disorders: Tumor Microenvironment Determinants of Immunotherapy Response

Joseph Schroers-Martin, MD, of Stanford University, discusses immunogenomic features reflecting divergent biology in posttransplant lymphoproliferative disorders (PTLD). These include evidence of mismatch repair defects in Epstein-Barr virus–positive PTLD, tumor microenvironment depletion, and MYC...

supportive care
hematologic malignancies

Managing the Risk of Thrombosis in Polycythemia Vera

This is Part 1 of Updates in Myeloproliferative Neoplasms, a three-part video roundtable series. Stay tuned for future installments in the coming months.   In this video, Dr. Prithviraj Bose and Dr. Ruben Mesa discuss how best to manage the risk of thrombosis in patients with polycythemia vera....

hematologic malignancies
supportive care

Leslie S. Kean, MD, PhD, on Bone Marrow Transplantation: Using Abatacept to Prevent Graft-vs-Host Disease

Leslie S. Kean, MD, PhD, of Dana-Farber/Boston Children's Cancer and Blood Disorders Center, discusses findings from her analysis of the International Blood and Marrow Transplant Research Database, which led to the recent FDA approval of abatacept for the prevention of acute graft-vs-host disease...

hematologic malignancies

Ronald S. Go, MD, on Managing Histiocytic Neoplasms: New NCCN Guidelines

Ronald S. Go, MD, of Mayo Clinic Cancer Center, discusses the new NCCN Clinical Practice Guidelines in Oncology for the most common types of histiocytic neoplasms in adults—Erdheim-Chester disease, Langerhans cell histiocytosis, and Rosai-Dorfman disease, all considered rare among hematologic...

hematologic malignancies
leukemia
immunotherapy

Alexey V. Danilov, MD, PhD, on Lymphoid Malignancies: Novel Agents Targeting BTK Inhibitor–Resistant Disease

Alexey V. Danilov, MD, PhD, of City of Hope, discusses the uses and side effects of cellular and immune therapies, including venetoclax and obinutuzumab, which may prove to be effective in treating highly resistant lymphoid malignancies such as chronic lymphocytic leukemia.

supportive care
hematologic malignancies

Jared E. Matya, PharmD, BCOP, on Supportive Therapies for Side Effects Related to Novel Oral Treatments

Jared E. Matya, PharmD, BCOP, of Nebraska Medicine, discusses oral agents and their toxicity profiles, as well as newer-generation agents that are often more selective and better tolerated. He describes how toxicity monitoring and management help to ensure patients with cancer remain on treatment.

hematologic malignancies
immunotherapy
global cancer care

Peihua (Peggy) Lu, MD, on CAR T-Cell Therapy: Research in China

Peihua Lu, MD, of Lu Daopei Hospital, discusses the state of research in China on CAR T-cell therapy, placing it in the context of the global development pipeline and the progress being made.

hematologic malignancies

Ruben A. Mesa, MD, on Myelofibrosis, Transfusion Independence, and Momelotinib

Ruben A. Mesa, MD, of UT Health San Antonio Cancer Center, discusses new findings on momelotinib, a potent JAK1, JAK2, and ACVR1 inhibitor with clinical activity against hallmark features of myelofibrosis such as anemia and splenomegaly. Results showed that transfusion independence was associated...

hematologic malignancies

Claire Harrison, MD, DM, on Myelofibrosis: Fedratinib as First-Line Therapy After Prior Ruxolitinib

Claire Harrison, MD, of Guy’s and St. Thomas’ Hospital, discusses survival results from the JAKARTA and JAKARTA2 trials, which showed that fedratinib, an oral JAK2 inhibitor, significantly improved progression-free survival vs placebo as a first-line treatment for patients with myelofibrosis...

hematologic malignancies
immunotherapy

Efstathios Kastritis, MD, on Amyloidosis: Standard of Care Plus Daratumumab

Efstathios Kastritis, MD, of the University of Athens, discusses updated phase III results from the ANDROMEDA study of patients with newly diagnosed light chain amyloidosis. The trial further supports the use of daratumumab plus VCd (bortezomib, cyclophosphamide, and dexamethasone), which was shown ...

hematologic malignancies
immunotherapy

Andrew D. Zelenetz, MD, PhD, and Stephen J. Schuster, MD, on CAR T Cells for Hematologic Malignancies: Where We’re At

hematologic malignancies
lymphoma
multiple myeloma
issues in oncology
palliative care

Lena E. Winestone, MD, MSHP, on Health-Care Disparities in Hematologic Cancers: Real-World Data

Lena E. Winestone, MD, MSHP, of the University of California, San Francisco and Benioff Children’s Hospital, reviews different aspects of bias in treatment delivery, including patient selection for clinical trials; racial and ethnic disparities in survival for indolent non-Hodgkin diffuse large...

hematologic malignancies
genomics/genetics

Jyoti Nangalia, MBBChir, on MPN: A New Paradigm for the Development of Blood Cancer?

Jyoti Nangalia, MBBChir, of Wellcome Sanger Institute and the University of Cambridge, discusses how her team used large-scale whole-genome sequencing to precisely time the origins of a blood cancer­­­­­ and measure how it grew. The information could provide opportunities for early diagnosis and...

hematologic malignancies
issues in oncology

Radhika Gangaraju, MD, and Smita Bhatia, MD, MPH, on Coronary Heart Disease Risk in Blood or Marrow Transplant Survivors

Smita Bhatia, MD, MPH, and Radhika Gangaraju, MD, both of the Institute for Cancer Outcomes and Survivorship, University of Alabama at Birmingham, discuss findings that showed survivors of bone marrow transplants are at a 7- to 12-fold higher risk of coronary heart disease than a sibling comparison ...

Advertisement

Advertisement




Advertisement